Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

Next Previous
Trial Profile

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ketoprofen (Primary) ; Pentoxifylline (Primary) ; Pirfenidone (Primary) ; Pravastatin (Primary) ; Tocopherol (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Acronyms Reverse-fibrose

Most Recent Events

  • 24 Jul 2026 Planned End Date changed from 1 Mar 2033 to 31 Jul 2031.
  • 24 Jul 2026 Planned primary completion date changed from 1 Mar 2031 to 31 Jul 2030.
  • 10 Oct 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top